For atopic asthma, many monoclonal antibodies were developed and showed potential effects: Omalizumab [36] and Dupilumab [37] are both monoclonal antibodies that bind to IgE and IL-4Rα respectively, and may be treatment options when atopic asthma is persistent and inadequately controlled by ICS. This evidence concerns the gene IL4R and atopic asthma.